Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This paper discusses the challenges of diagnosing drug eruptions, emphasizing the nonspecific patterns and unclear pathomechanisms, and calls for further research using new biologic drugs to understand these reactions better.

This review discusses the various skin, mucosa, and adnexa side effects associated with different chemotherapeutic agents and provides insights into their clinical presentation and management; it reports no new results.

Transplant patients often get skin problems, with treatments varying by condition.

This case report from the study described a 62-year-old woman with pityriasis rubra pilaris and Kaposi's varicelliform eruption, whose skin condition improved significantly with isotretinoin treatment over 43 weeks.

This case report describes a young patient with a unique combination of dysmorphism, bullous eruption, skin and muscle atrophy, and hyperpigmentation that doesn't fit existing nosological categories.

This review outlines dermatological toxicities associated with targeted cancer therapies and immunotherapies, emphasizing the need for collaborative management by oncologists and dermatologists but reports no new clinical findings.

This article reviews the identification and assessment of cutaneous drug reactions, emphasizing the importance of early recognition and the need for accurate diagnosis to prevent serious complications; it reports no new clinical results.

Any drug can cause skin reactions, but antibiotics, NSAIDs, and psychotropic drugs are more common, with some reactions being life-threatening.

This article reviews the cutaneous side effects of immune checkpoint inhibitors and targeted therapies for skin cancers, noting that while generally mild, these effects can influence treatment decisions and quality of life, underscoring the need for physicians to be aware of these adverse reactions.

This case report highlights that Demodex folliculitis in an immunocompromised patient can result in severe and widespread eruptions, which were effectively treated with oral ivermectin and topical permethrin.

This study found that the administration of the mutant BRAF inhibitor dabrafenib in patients with metastatic melanoma was associated with various skin lesions, including keratinocytic proliferation that sometimes showed low-grade malignancy features.

This study reports that Iressa, an anti-cancer agent, commonly causes acneiform eruptions and xerosis as cutaneous side effects, similar to other agents targeting epidermal growth factor receptors.

This systematic review reports that "COVID toes" and other skin manifestations can be initial signs of COVID-19, and advises immunosuppressive therapy adjustments only for infected or at-risk patients.

This review discusses the complex pathophysiological and clinical aspects of COVID-19, including dermatological findings and their association with SARS-CoV-2 infection but reports no new clinical results.

This study observed that 13 out of 38 children with methylmalonic and propionic acidaemia exhibited specific cutaneous manifestations, suggesting these conditions may include skin symptoms more often than previously thought.

This review discusses the range of cutaneous side-effects caused by EGFR inhibitors in cancer therapy and explores available treatment options, without reporting new clinical findings.

In this study, multiple cutaneous adverse effects were observed in patients with metastatic malignant melanoma receiving BRAF inhibitors, but most were well managed with appropriate treatment.

In this study, 96% of children with CNS tumors receiving MAPK and mTOR inhibitors experienced common, treatable skin reactions, occasionally requiring therapy adjustments.

This review examines nonmalignant skin toxicities from immunosuppressive and transplant-related medications, emphasizing the need for effective identification and management by care providers; it presents no new research findings.

In this prospective study, dabrafenib and trametinib were associated with various skin side effects, including papillomas, hyperkeratosis, and acneiform eruptions in patients with metastatic melanoma.

This retrospective study found a variety of dermatological adverse events associated with antineoplastic treatments, often leading to changes or suspension of cancer therapies in affected patients.

This study found no increased frequency of the TNF2 allele in Mexican patients with adverse cutaneous drug reactions mediated by delayed hypersensitivity, suggesting its lower relevance compared to findings in Caucasian populations.

This study reports that targeted anticancer therapies frequently cause skin-related side effects, which may impact patient adherence and quality of life, but these effects are positively correlated with treatment response.

This article discusses the range of skin-related side effects caused by chemotherapy and radiotherapy, including novel patterns emerging with targeted therapies, but does not report new clinical results.

This study discusses two cases of acneiform skin eruptions associated with the use of the EGFR inhibitor ZD1839 in prostate cancer treatment, emphasizing the need for dermatologists to be aware of potential skin reactions.

This expert consensus statement highlights that while targeted cancer therapies significantly improve patient survival, they often result in various skin toxicities, underscoring the need for early diagnosis, management, and multidisciplinary care to maintain patients' quality of life and ensure treatment continuity.

This study observed that physiological skin changes, especially pigmentary, were common in pregnant females, while specific dermatoses and fungal infections also occurred less frequently.

This source reviews the common skin-related side effects of tyrosine kinase inhibitors in treating endocrine cancers and emphasizes that proactive, multidisciplinary management can effectively control these adverse events without compromising cancer treatment efficacy.

This narrative review reports that IL-17 and IL-23 inhibitors, while effective for psoriasis and other inflammatory diseases, can cause a variety of skin reactions that resemble primary dermatoses, highlighting the need for careful diagnosis and varied management strategies.

Skin symptoms could help in early COVID-19 diagnosis but more research is needed to confirm their reliability.